Skip to main content
SpringerLink
Log in

Kalziumantagonisten

  • Chapter
Arterielle Hypertonie

  • 125 Accesses

Zusammenfassung

Kalziumantagonisten sind eine chemisch heterogene Substanzklasse, deren gemeinsames Merkmal es ist, den Einstrom von Kalziumionen durch spezifische membranöse Kanäle (sog. Kalziumkanäle vom L-Typ) erregbarer Zellen zu hemmen. Zur Behandlung der arteriellen Hypertonie wurden bislang nur selektive Kalziumantagonisten mit hoher Affinität zum Kalziumkanal vom L-Typ entwickelt, die sich aufgrund unterschiedlicher chemischer Strukturen, differenter Bindungsstellen am Kalziumkanal und einem — zumindest teilweise — differierenden Wirkungsspektrum in folgende drei Typen unterteilen lassen (Einzelsubstanzen s. Tabelle 26.1):

  • Phenylalkylaminderivate (Verapamil-Typ),

  • 1,4-Dihydropyridinderivate (Nifedipin-Typ) und

  • Benzothiazepinderivate (Diltiazem-Typ).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abernethy DR, Schwartz JB (1999) Calcium-antagonist drugs. N Engl J Med 341:1447–1457

    Article  PubMed  CAS  Google Scholar 

  • Alderman MH, Cohen H, Roque R, Madhaven S (1997) Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 349:594–598

    Article  PubMed  CAS  Google Scholar 

  • Anonymus (1995) Are calcium blockers safe for first-line therapy? The Genesis Report, June, pp 14–21

    Google Scholar 

  • Borchard U (1993) Kalziumantagonisten. Perspektiven für die 90er Jahre. Walter de Gruyter, Berlin New York S 1–122

    Google Scholar 

  • Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356:366–372

    Article  PubMed  CAS  Google Scholar 

  • Chobanian AV (1994) Can antihypertensive drugs reduce atherosclerosis and its clinical complications? Am J Hypertension 7:119S–125S

    CAS  Google Scholar 

  • Clinical implications of the World Health Organization International Society of Hypertension statement on calcium antagonists (1997) Psaty BM, Furberg CD. J Hypertension 15:1197–1200

    Article  Google Scholar 

  • Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO (1991) Morbidity and mortality in the Swedish trial in Old Patients with Hypertension (STOP-Hyperten-sion). Lancet 338:1281–1285

    Article  PubMed  Google Scholar 

  • Epstein M (1998) Calcium antagonists and renal protection: emerging perspectives. J Hypertension 16(suppl 4):S17–S25

    CAS  Google Scholar 

  • Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW (1998) The effects of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645–652

    Article  PubMed  CAS  Google Scholar 

  • Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeld D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S for the HOT Study Group (1998) Effects of intensive blood lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762

    Article  PubMed  CAS  Google Scholar 

  • Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen O, Lanke J, de Faire U, Dahlöf B, Karlberg BE, for the NORDIL Study Group, (2000) Randomised trial of effects of calcium antagonists compared with diuretics and-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356:359–365

    Article  PubMed  CAS  Google Scholar 

  • Hole DJ, Gillis CR, McCallum IR et al. (1998) Cancer risk of hypertensive patients taking calcium antagonists. J Hypertension 16:119–124

    Article  CAS  Google Scholar 

  • Lijnen P (1995) Once-daily antihypertensive treatment with calcium antagonists. Drugs Today 31:283–292

    CAS  Google Scholar 

  • Liischer TF, Cosentino F (1998) The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal. Drugs 55:509–517

    Article  Google Scholar 

  • Meier CR, Derby LE, Jick SS, Jick H (2000) Angiotensin-Converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 160:349–353

    Article  PubMed  CAS  Google Scholar 

  • Mimran A, Ribstein J (1994) Angiotensin-Converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertension 7:73S–81S

    CAS  Google Scholar 

  • Opie LH (1990) Clinical use of calcium channel antagonist drugs. 2nd ed. Kluwer Academic Publishers, Boston Dordrecht London pp 1–326

    Google Scholar 

  • Opie LH, Messerli FH (1995) Nifedipine and mortality. Grave defects in the dossier. Circulation 92:1068–1073

    Article  PubMed  CAS  Google Scholar 

  • Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB, Havlik RJ (1996) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348:493–497

    Article  PubMed  CAS  Google Scholar 

  • Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274:620–625

    Article  PubMed  CAS  Google Scholar 

  • Steele RM, Schuna AA, Schreiber RT (1994) Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 120:663–664

    PubMed  CAS  Google Scholar 

  • Tatti P, Pahor M, Byington RP, Di Auro P, Guarisco R, Strollo G, Strollo F (1998) Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597–603

    Article  PubMed  CAS  Google Scholar 

  • Toyo-Oka T, Nayler WG (1996) Third generation calcium entry blockers. Blood Press 5:206–208

    Article  PubMed  CAS  Google Scholar 

  • Tuomilehto J, Rastenyte D, Birkenhäger WH, Thiijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R for the Systolic Hypertension In Europe Trial Investigators (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340:677–684

    Article  PubMed  CAS  Google Scholar 

  • Wang LL, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group (2000) Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 160:211–220

    Article  PubMed  CAS  Google Scholar 

  • Yusuf S (1995) Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation 92:1079–1082

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reha Klinik GmbH Damp, Postfach 3000, 24349, Damp, Germany

    Prof. Dr. med. Michael Stimpel (Medizinische Fakultät der Universität zu Köln Ärztlicher Direktor der Fachkliniken für Rehabilitation und Präventivmedizin Damp und Schloß Schönhagen)

Authors
  1. Prof. Dr. med. Michael Stimpel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Stimpel, M. (2001). Kalziumantagonisten. In: Arterielle Hypertonie. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57617-1_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57617-1_26

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63309-6

  • Online ISBN: 978-3-642-57617-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation